Prognostic role of genetic biomarkers in clinical progression of prostate cancer

Experimental and Molecular Medicine

Volumn 47, Issue 8, 2015, Pages

  Alvarez Cubero, Maria Jesus ^a,b   Martinez Gonzalez, Luis Javier ^b   Saiz, Maria ^a   Carmona Saez, Pedro ^b   Alvarez, Juan Carlos ^a   Pascual Geler, Manrique ^c   Lorente, Jose Antonio ^a,b   Cozar, Jose Manuel ^c  

^a UNIVERSITY OF GRANADA   (Spain)

^b PTS Granada   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2-5A-DEPENDENT RIBONUCLEASE; ELAC2 PROTEIN, HUMAN; GENETIC MARKER; MSR1 PROTEIN, HUMAN; RIBONUCLEASE; SCAVENGER RECEPTOR A; TUMOR PROTEIN;

AGED; COHORT ANALYSIS; DISEASE COURSE; GENE FREQUENCY; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; DISEASE PROGRESSION; ENDORIBONUCLEASES; GENE FREQUENCY; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS; SCAVENGER RECEPTORS, CLASS A;

EID: 84945127819     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/EMM.2015.43     Document Type: Article

References (23)

1. Borque Á, del Amo J, Esteban LM, Ars E, Hernández C, Planas J et al. Genetic predisposition to early recurrence in clinically localized prostate cancer. BJU Int 2012; 111: 549–558.
2. Lin H, Amankwah EK, Tseng T, Qu X, Chen D, Park JY.. SNP-SNP interaction network in angiogenesis genes associated with prostate cancer aggressiveness. PLoS ONE 2013; 8: e59688.
3. Choudhury AD, Eeles R, Freedland SJ, Isaacs WB, Pomerantz MM, Schalken JA et al. The role of genetic markers in the management of prostate cancer. Eur Urol 2012; 62: 577–587.
4. Carlsson S, Maschino A, Schröder F, Bangma C, Steyerberg EW, van der Kwast T et al. Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prosta-tectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer Section Rotterdam. Eur Urol 2013; 64: 693–699.
5. Obort AS, Ajadi MB, Akinloye O. Prostate-specific antigen: any successor in sight? Reviews in urology 2013; 15: 97.
6. Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J et al. Human prostate cancer risk factors. Cancer 2004; 101(10 Suppl): 2371–2490.
7. Rennert H, Zeigler-Johnson C, Mittal RD, Tan YC, Sadowl CM, Edwards J et al. Analysis of the RNASEL/HPC1, and macrophage scavenger receptor 1 in Asian-indian advanced prostate cancer. Urology 2008; 72: 456–460.
8. Bisbal C, Silverman RH. Diverse functions of RNase L and implications in pathology. Biochimie 2007; 89: 789–798.
9. Hughes C, Murphy A, Martin C, Sheils O, O'Leary J. Molecular pathology of prostate cancer. J Clin Pathol 2005; 58: 673–684.
10. Peiser L, Gordon S. The function of scavenger receptors expressed by macrophages and their rolein the regulation of inflammation. Microbes Infect 2001; 3(2): 149–159.
11. Minagawa A, Takaku H, Takagi M, Nashimoto M. The missense mutations in the candidate prostate cancer gene ELAC2 do not alter enzymatic properties of its product. Cancer Lett 2005; 222: 211–215.
12. Beuten J, Gelfond JAL, Franke JL, Shook S, Johnson-Pais TL, Thompson IM et al. Single and multivariate associations of MSR1, ELAC2, and RNASEL with prostate cancer in an ethnic diverse cohort of men. Cancer Epidem Biomar 2010; 19: 588–599.
13. Oh J, Byun S, Lee S, Hong SK, Jeong CW, Choi WS et al. Genetic variants in the CYP24A1 gene are associated with prostate cancer risk and aggressiveness in a Korean study population. Prostate Cancer Prostatic Dis 2014; 17: 149–156.
14. Barnett CM, Heinrich MC, Lim J, Nelson D, Beadling C, Warrick A et al. Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer. Clin Cancer Res 2014; 20: 1306–1312.
15. Kashyap A, Kluźniak W, Wokołorczyk D, Gołąb A, Sikorski A, Słojewski M et al. The presence of prostate cancer at biopsy is predicted by a number of genetic variants. Int J Cancer 2014; 134: 1139–1146.
16. Gray IC, Campbell DA, Spurr NK. Single nucleotide polymorphisms as tools in human genetics. Hum Mol Genet 2000; 9: 2403–2408.
17. Katsanis SH, Katsanis N.. Molecular genetic testing and the future of clinical genomics. Nat Rev Genet 2013; 14: 415–426.
18. Cybulskia C, Wokołorczyka D, Jakubowskaa A, Gliniewicz B, Sikorski A, Huzarski T et al. DNA variation in MSR1, RNASEL and E-cadherin genes and prostate cancer in Poland. Eur Urol Suppl 2009; 8: 567–605.
19. Solé X, Guinó E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics 2006; 22: 1928–1929.
20. Roddam AW, Duffy MJ, Hamdy FC, Jung K. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2–10 ng/ml: systematic review and meta-analysis. Eur Urol 2005; 48: 386–399.
21. Garcia-Closas M, Couch FJ, Lindstrom S, Michailidou K, Schmidt MK, Brook MN et al. Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet 2013; 45: 392–398.
22. Rennert H, Zeigler-Johnson CM, Addya K, Finley MJ, Walker AH, Spangler E et al. Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men. Cancer Epidem Biomar 2005; 14: 949–957.
23. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61: 1079–1092.